Table 2.
Response to eribulin/olaparib combination treatment by patients relative to immunohistochemistry status
| Responders | Non-responders | P value | |||
|---|---|---|---|---|---|
| BRCA1 n = 29 |
pos | 17 (58.6%) | 5 | 12 | .260 |
| neg | 12 (41.4%) | 6 | 6 | ||
| BRCA2 n = 28 |
pos | 15 (53.6%) | 6 | 9 | .934 |
| neg | 13 (46.4%) | 5 | 8 | ||
| EGFR n = 28 |
pos | 12 (42.9%) | 4 | 8 | .576 |
| neg | 16 (57.1%) | 7 | 9 | ||
| CK5/6 n = 29 |
pos | 4 (13.8%) | 2 | 2 | .592 |
| neg | 25 (86.2%) | 9 | 16 | ||
| E-cadherin n = 28 |
pos | 3 (10.7%) | 0 | 3 | .140 |
| neg | 25 (89.3%) | 11 | 14 | ||
| ZEB1 n = 28 |
pos | 3 (10.7%) | 2 | 1 | .304 |
| neg | 25 (89.3%) | 9 | 16 | ||
| Vimentin n = 28 |
pos | 19 (67.9%) | 8 | 11 | .657 |
| neg | 9 (32.1%) | 3 | 6 |
pos: positive, neg: negative.
chi-square test.